A KFF Health News analysis highlighted gaps in FDA-ordered postmarket studies, showing that long-running safety follow-ups can lag far behind original timelines. Using Tavneos as an example—approved with a requirement for additional years-long safety data—the reporting found enrollments stalled and liver injury cases were identified, illustrating how delayed studies can leave clinicians and patients without complete risk clarity.